Drug Response Dx Closes First Round of Financing

Drug Response Dx, a Hennigsdorf, Germany-based developer of proprietary RA biomarkers based on technology licensed from Max-Planck-Innovation, closed itd first round of financing.

Backers included QIAGEN and High-Tech Gründerfonds.

Founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter, Drug Response Dx aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.

The company intends to use the capital, whose amount was not disclosed, to advance its biomarker test kit for rheumatoid arthritis treatment. A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities.



Join the discussion